Cited by 171Cystic Fibrosis Research AdvancesDiabetes Management and ResearchDiabetes Treatment and Management

ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents

Open access
Moran, Antoinette, Pillay, Kubendran, Becker, Dorothy, Granados, Andrea, Hameed, Shihab, Acerini, Carlo L.·2018·Pediatric Diabetes

Abstract

Since the original guidelines were published, there has been additional work done to characterize the pathophysiology of cystic fibrosisrelated diabetes (CFRD), including the role of genes related to type 2 diabetes, the role of inflammation, and the potential role of the basic CF transmembrane conductance regulator (CFTR) chloride channel defect.Continuous glucose monitoring (CGM) data have better defined the daily glucose excursions that occur in CF and their relation to HbA1c and mean glucose level.There are currently no major changes in the clinical guidelines.On the horizon, the results of two ongoing studies examining the role of insulin therapy in non-diabetic CF patients with abnormal glucose tolerance may eventually change recommendations for this population.Likewise, new CF corrector/ modulator drugs may have a profound impact on the course of CFRD and its treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pedi.12732

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CFRD is the most common comorbidity in people with cystic fibrosis, occurring in about 20% of adolescents and 40-50% of adults.

    “Cystic fi brosis -related diabetes (CFRD) is the most common comorbidity in people with cystic fi brosis, occurring in about 20% of adolescents and 40 -50% of adults (125).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 15

  1. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose toler- ance in cystic fibrosis: a five year prospective study. BMJ. 1995;311: 655-659.
  2. Dobson L, Sheldon CD, Hattersley AT. Conventional measures under- estimate glycaemia in CF patients. Diabet Med. 2004;21:691-696.
  3. O'Riordan SM, Hoey H, Costigan C. Demographics and prevalence of glucose intolerance and cystic fibrosis related diabetes in 167 cystic fibrosis children. Diabetes. 2006;55:A224.
  4. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes melli- tus in CF is characterized by islet amyloidosis. J Clin Endocrinol Metab. 1996;81:1267-1272.
  5. Holl RW, Wolf A, Thon A, et al. Insulin resistance with altered secre- tory kinetics and reduced proinsulin in CF patients. J Pediatr Gastroen- terol Nutr. 1997;25:188-193.
  6. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. CFRD: the role of peripheral insulin resistance and beta-cell dysfunc- tion. Diabet Med. 2002;19:221-226.
  7. Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitiv- ity and insulin clearance in CF patients with normal and diabetic glu- cose tolerance. Clin Endocrinol. 1994;41:217-223.
  8. Boom A, Lybaert P, Pollet JF, et al. Expression and localization of CFTR in the rat endocrine pancreas. Endocr Pract. 2008;32:197-205.
  9. Bellin MD, Laguna T, Leschyshyn J, et al. Proof-of-concept pilot: insu- lin secretion improves in cystic fibrosis following ivacaftor correction of CFTR. Pediatr Diabetes. 2013;14:417-421.
  10. Georgiopolou W, Denker A, Bishop KL, et al. Metabolic abnormalities in adults with CF. Respirology. 2010;15:823-829.
  11. Rhodes B, Nash EF, Tullis E, et al. Prevalence of dyslipidemia in adults with CF. J Cyst Fibros. 2010;9:24-28.
  12. Rolon MA, Benali K, Munck A, et al. CFRD: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001;90: 860-867.
  13. Martin-Frias M, Lamas Ferreiro A, Enes Romero P, Cano Gutierrez B, Barrio CR. Abnormal glucose tolerance in prepubertal patients with cystic fibrosis. An Pediatr (Barc). 2012;77:339-343.
  14. Konrad K, Thon A, Fritsch M, et al. Comparison of CFRD with T1D based on a German/Austrian pediatric diabetes registry. Diabetes Care. 2012;35:1-8.
  15. Moran A. Is it time to treat CFRD with oral diabetes agents? Lancet Diabetes Endocrinol. 2018;6:85-87.

Cited by

Sorted by citations

Authors
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L.
Affiliations
  • University of Minnesota (US)
  • Westville Hospital; Durban South Africa
  • Children's Hospital of Pittsburgh (US)
  • Washington University in St. Louis (US)
  • UNSW Sydney (AU)
  • University of Cambridge (GB)
Corresponding author
Moran, Antoinette
Venue
Pediatric Diabetes
Publisher
Wiley
Published
2018-10
Volume
19
Pages
64-74
ISSN
1399-543X (ISSN-L)
OpenAlex
W1504170793
Cited by
171
References
94
Citations by year
2026: 10 · 2025: 6 · 2024: 14 · 2023: 31 · 2022: 34 · 2021: 30 · 2020: 25 · 2019: 14 · 2018: 2 · 2017: 3 · 2015: 1
FWCI
13.37
Type
journal article
Language
en
Open access
Locations
  • Pediatric Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
cystic fibrosis-related diabetes, children and adolescents, insulin therapy, continuous glucose monitoring, glycemic excursions, HbA1c, CFTR modulator therapy, inflammation, impaired glucose tolerance, diabetes management
MeSH terms
Adolescent, Child, Cystic Fibrosis, Diabetes Mellitus, Diagnostic Techniques, Endocrine, Endocrinology, Humans, International Cooperation, Pediatrics, Practice Patterns, Physicians', Societies, Medical, Incidence, Prevalence, Age of Onset, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review